The mapping of the human genome has provided medical professionals with the ability to refine a patient’s cancer risk through the analysis of inherited mutations.
Luminus’ genetic tests screen a number of known genes related to hereditary cancers. The goal of every test is to determine a patient’s risk of cancer. This knowledge can help your physician to develop the appropriate or preventative treatment plan for early detection. If the results of your test indicate an increased risk for cancer, your doctor may order tests like mammograms, colonoscopy and CT scans for any possible diagnosis and immediate intervention.
Breast Cancer Panel BRCA1 and BRCA2
Having mutations in either the BRCA1 or the BRCA2 gene significantly increases a patient’s risk for breast, ovarian and other types of cancer.
High Risk Breast Cancer Panel
(Ashkenazi Jewish, Hispanic with Reflexive options)
High Risk Panel is a next-generation sequencing test with deletion/duplication analysis to detect mutations in seven high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2. Three independent testing platforms include 3 site Ashkenazi Jewish panel and 8 site Hispanic testing panel.
Recent studies of breast cancer survivors have shown that approximately 70 percent of the mutations identified were BRCA1/2 mutations. Approximately 4 percent had germline mutations in other cancer-susceptibility genes, including high-risk genes. These additional high-risk genes include CDH1, PALB2, PTEN, STK11, and TP53. Luminus Diagnostics Breast High Risk Panel analyzes all of these genes.
Colorectal Cancer Panel
According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, colorectal cancer is the second leading cause of cancer-related death in the United States, and the third most commonly diagnosed cancer in men and women. Overall, 1 in 20 individuals will develop colorectal cancer at some point during their life – equating to a 5% lifetime risk of developing colorectal cancer. Although the majority of colorectal cancer is sporadic, and caused by a variety of genetic and non-genetic factors, research has shown that approximately 5% of colorectal cancers are due to hereditary changes in single genes.
Lynch Syndrome
Luminus Lynch Syndrome genetic testing is a hereditary cancer panel designed for individuals suspected to be at-risk for Lynch (hereditary non-polyposis colon cancer or HNPCC) syndrome. Testing includes full sequencing of MLH1, MSH2, MSH6, and PMS2. Testing also includes deletion/duplication analysis for these four genes as well as the EPCAMgene.
